Drug Profile
Research programme: anticancer therapeutics - Rhizen/Incozen
Alternative Names: RP-10107Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Incozen Therapeutics; Rhizen Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Glutaminase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in India (PO)
- 28 May 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in Switzerland (PO)
- 28 May 2022 No recent reports of development identified for preclinical development in Solid-tumours in India (PO)